Accelerating the Elimination of Viral Hepatitis: a Lancet Gastroenterology & Hepatology Commission.
Authors
Cooke, GSAndrieux-Meyer, I
Applegate, TL
Atun, R
Burry, JR
Cheinquer, H
Dusheiko, G
Feld, JJ
Gore, C
Griswold, MG
Hamid, S
Hellard, ME
Hou, J
Howell, J
Jia, J
Kravchenko, N
Lazarus, JV
Lemoine, M
Lesi, OA
Maistat, L
McMahon, BJ
Razavi, H
Roberts, TR
Simmons, B
Sonderup, MW
Spearman, WC
Taylor, BE
Thomas, DL
Waked, I
Ward, JW
Wiktor, SZ
Issue Date
2019-02-01Submitted date
2019-01-24
Metadata
Show full item recordAbstract
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.Publisher
ElsevierPubMed ID
30647010Language
enISSN
2468-1253ae974a485f413a2113503eed53cd6c53
10.1016/S2468-1253(18)30270-X
Scopus Count
Collections
Related articles
- Tuberculosis
- Authors: Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P, Holmes KK, Bertozzi S, Bloom BR, Jha P
- Issue date: 2017 Nov 3
- Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions.
- Authors: Duffell EF, Hedrich D, Mardh O, Mozalevskis A
- Issue date: 2017 Mar 2
- Global hepatitis C elimination: an investment framework.
- Authors: Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M
- Issue date: 2020 Oct
- Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
- Authors: Dunn R, Musabaev E, Razavi H, Sadirova S, Bakieva S, Razavi-Shearer K, Brigida K, Kamili S, Averhoff F, Nasrullah M
- Issue date: 2020 Aug 28
- Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
- Authors: Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, Scott N, Bulterys M, Ball A, Hirnschall G
- Issue date: 2019 Sep